|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
CA2055168A1
(en)
|
1990-11-21 |
1992-05-22 |
Walter Fiers |
Tnf-muteins
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US5753230A
(en)
|
1994-03-18 |
1998-05-19 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of angiogenesis
|
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
DE69536015D1
(de)
|
1995-03-30 |
2009-12-10 |
Pfizer Prod Inc |
Chinazolinone Derivate
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
GB9508537D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
EA001595B1
(ru)
|
1996-04-12 |
2001-06-25 |
Варнер-Ламберт Компани |
Необратимые ингибиторы тирозинкиназ
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
|
WO2003026577A2
(en)
|
2001-09-24 |
2003-04-03 |
Seattle Genetics, Inc. |
P-amidobenzylethers in drug delivery agents
|
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
|
CA2467242A1
(en)
|
2001-11-20 |
2003-05-30 |
Seattle Genetics, Inc. |
Treatment of immunological disorders using anti-cd30 antibodies
|
|
JP4272537B2
(ja)
|
2002-03-13 |
2009-06-03 |
北京鍵▲凱▼科技有限公司 |
Ｙ型分鎖親水性ポリマー誘導体、それらの調製方法、前記誘導体および薬剤分子の結合生成物、ならびに前記結合生成物を含む医薬組成物
|
|
US7456260B2
(en)
|
2002-06-17 |
2008-11-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Humanized antibody
|
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
|
US20050180972A1
(en)
|
2002-07-31 |
2005-08-18 |
Wahl Alan F. |
Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
|
DE602004017726D1
(de)
|
2003-06-30 |
2008-12-24 |
Domantis Ltd |
Pegylierte Single-domain-antikörper (dAb)
|
|
NZ579482A
(en)
|
2004-06-01 |
2011-02-25 |
Genentech Inc |
Antibody drug conjugates and methods
|
|
GB0521621D0
(en)
|
2005-10-24 |
2005-11-30 |
Domantis Ltd |
Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
|
|
US9081017B2
(en)
|
2005-04-11 |
2015-07-14 |
Cambridge Enterprise Limited |
Methods for identifying modulators of tumor necrosis factor receptors
|
|
JP2009539412A
(ja)
|
2006-06-12 |
2009-11-19 |
レセプター バイオロジックス， インコーポレイテッド |
汎細胞表面レセプター特異的な治療薬
|
|
WO2008052108A2
(en)
|
2006-10-26 |
2008-05-02 |
Centocor Ortho Biotech Inc. |
Methods for use in human-adapting monoclonal antibodies
|
|
GB0724331D0
(en)
|
2007-12-13 |
2008-01-23 |
Domantis Ltd |
Compositions for pulmonary delivery
|
|
CA2688433A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Methods for selecting protease resistant polypeptides
|
|
CN102321155A
(zh)
*
|
2008-12-19 |
2012-01-18 |
华中科技大学 |
Tnf结合肽和tnfr1封闭肽及其在治疗溃疡性结肠炎中的应用
|
|
AU2010215479B2
(en)
|
2009-02-19 |
2015-01-22 |
Glaxo Group Limited |
Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists
|
|
WO2011008814A2
(en)
|
2009-07-14 |
2011-01-20 |
Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation |
Multiplexed measurement of exogenous and endogenous dna
|
|
JP2012532619A
(ja)
|
2009-07-16 |
2012-12-20 |
グラクソ グループ リミテッド |
Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
|
|
JP2013507978A
(ja)
|
2009-10-27 |
2013-03-07 |
グラクソ グループ リミテッド |
安定な抗ｔｎｆｒ１ポリペプチド、抗体可変ドメイン及びアンタゴニスト
|
|
SE1150065A1
(sv)
|
2011-01-31 |
2012-07-17 |
Fairchild Semiconductor |
Bipolär transistor i kiselkarbid med övervuxen emitter
|
|
WO2012172070A1
(en)
|
2011-06-17 |
2012-12-20 |
Glaxo Group Limited |
Tumour necrosis factor receptor 1 antagonists
|
|
PE20141522A1
(es)
*
|
2011-08-17 |
2014-11-17 |
Glaxo Group Ltd |
Proteinas y peptidos modificados
|
|
EP3738605A1
(en)
|
2012-09-10 |
2020-11-18 |
Xencor, Inc. |
Methods of treating neurological diseases
|
|
EP3936137A1
(en)
|
2013-02-07 |
2022-01-12 |
The General Hospital Corporation |
Methods for expansion or depletion of t-regulatory cells
|
|
WO2015104322A1
(en)
|
2014-01-09 |
2015-07-16 |
Glaxosmithkline Intellectual Property Development Limited |
Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
|
|
US10508151B2
(en)
*
|
2014-11-19 |
2019-12-17 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
US20190135929A1
(en)
|
2015-08-28 |
2019-05-09 |
The General Hospital Corporation |
Agonistic anti-tumor necrosis factor receptor 2 antibodies
|
|
UA120981C2
(uk)
*
|
2015-09-18 |
2020-03-10 |
Чугаі Сейяку Кабусікі Кайся |
Антитіло, що зв'язується з il-8, та його застосування
|
|
US11859002B2
(en)
|
2016-05-13 |
2024-01-02 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor 2 antibodies
|
|
EP3606949A1
(en)
|
2017-04-06 |
2020-02-12 |
Universität Stuttgart |
Tumor necrosis factor receptor (tnfr) binding protein complex with improved binding and bioactivity
|
|
WO2019226750A1
(en)
|
2018-05-23 |
2019-11-28 |
Kantum Diagnostics, Inc. |
Methods of treating and preventing renal inflammation by inhibiting udp-hexose signaling
|
|
EP3927828A4
(en)
|
2019-02-21 |
2023-02-01 |
Enosi Life Sciences Corp. |
ANTIBODIES AND ENONOMERS
|